First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with other solid tumors: Safety and efficacy results from a phase I study.

被引：0
|
作者：
Bai, Xueli
Xu, Qin
Liang, Xinjun
Chu, Qian
Zhang, Xiaochen
Chen, Yiwen
Xu, Nong
Fang, Weijia
Shan, Jianzhen
Jiang, Weiqin
Zhou, Jianya
Zheng, Yu-Long
Long, Sixiang
Chen, Haonan
Zhao, Li
Wang, Hongli
Sun, Jiya
Sun, Xing
Zhou, Hui
Liang, Tingbo
机构：
[1] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Peoples R China
[2] Fujian Prov Canc Hosp, Dept Gynecol Oncol, Fuzhou, Peoples R China
[3] Hubei Canc Hosp, Dept Abdominal Oncol, Wuhan, Peoples R China
[4] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Wuhan, Peoples R China
[5] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Hepatopancreatobiliary Surg, Hangzhou, Peoples R China
[6] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Med Oncol, Hangzhou, Peoples R China
[7] Innovent Biol Suzhou Co Ltd, Suzhou, Peoples R China
[8] Innovent Biol Suzhou Co Ltd, Beijing, Peoples R China
[9] Innovent Biol Suzhou Co Ltd, Shanghai, Peoples R China
[10] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Hepatobiliary & Pancreat Surg, Hangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14593
引用
收藏
页数：1
相关论文
共 50 条
  • [21] PHASE II STUDY TO ASSESS THE SAFETY AND EFFICACY OF THE CLEVER-1 ANTIBODY BEXMARILIMAB IN COMBINATION WITH PD-1 BLOCKADE IN PATIENTS WITH ADVANCED SOLID TUMORS - BEXCOMBO
    Bono, Petri
    Jalkanen, Juho
    Pawlitzky, Inka
    Fjaellskog, Marie-Louise
    Ahlin, Cecilia
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A742 - A742
  • [22] Phase I study of IBI322 (anti-CD47/PD-L1 bispecific antibody) monotherapy therapy in patients with advanced solid tumors in China.
    Wang, Jie
    Sun, Yuping
    Chu, Qian
    Duan, Jianchun
    Wan, Rui
    Wang, Zhijie
    Zhao, Jun
    Li, Haoyuan
    Guo, Yingmei
    Chen, Yuling
    Wang, Yan
    CANCER RESEARCH, 2022, 82 (12)
  • [23] Preliminary safety and pharmacodynamic (PD) activity of XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in a phase I dose escalation study of patients with selected advanced solid tumors.
    Hickingbottom, Barbara
    Clynes, Raphael
    Desjarlais, John
    Li, Caiyan
    Ding, Ying
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [24] Phase I safety and preliminary efficacy of PM1003, a bispecific antibody targeting PD-L1 and 4-1BB, in patients with advanced solid tumors
    Xue, Junli
    Sun, Yuping
    Li, DaPeng
    Guo, Ye
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] Initial results from a phase 1a/1b study of STK-012, a first-in-class α/β IL-2 receptor biased partial agonist in advanced solid tumors (NCT05098132)
    Izar, Benjamin
    Zamarin, Dmitriy
    Spigel, David R.
    Hoimes, Christopher J.
    McDermott, David F.
    Sehgal, Kartik
    Najjar, Yana G.
    Schoenfeld, Adam J.
    Garon, Edward B.
    Sullivan, Ryan J.
    Henick, Brian S.
    Leal, Ticiana A.
    Hurwitz, Michael E.
    McKay, Rana R.
    Busby, Natalie
    Mehta-Damani, Anita
    Azrilevich, Alex
    Tran, Tony
    Rizvi, Naiyer
    Oft, Martin
    Spira, Alexander I.
    CANCER RESEARCH, 2024, 84 (07)
  • [26] Safety and preliminary efficacy results of IBI389, an anti-CLDN18.2/CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: A phase 1 dose escalation and expansion study
    Zheng, Li
    Dai Ruihong
    Ying Jieer
    Xu, Qi
    Guo, Zengqing
    Hu, Changlu
    Sun, Yuping
    Niu, Zuoxing
    Hao, Jihui
    Zhang, Mingjun
    Dai Guanghai
    Hua, Dong
    Pan, Yueyin
    Wang, Xin
    Wei, Shuqing
    Chen, Xiaobing
    Yu, Xinhe
    Zhang, Yulong
    Zhou, Hui
    Bi, Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] A phase I study of AK112, a bispecific antibody that targets PD-1 and VEGF co-expressing T cells, in patients with advanced solid tumors.
    Coward, Jermaine
    Lemech, Charlotte Rose
    Mislang, Anna Rachelle Austria
    Parakh, Sagun
    Underhill, Craig
    Nagrial, Adnan
    Jin, Xiaoping
    Li, Baiyong
    Wang, Zhongmin Maxwell
    Kwek, Kon Yew
    Xia, Yu
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [28] Safety, Tolerability, and Preliminary Efficacy of Serplulimab, a Novel Anti-PD-1 Antibody, in Patients with Metastatic or Recurrent Solid Tumors: A Phase I Study
    Ho, Ching-Liang
    Chao, Tsu-Yi
    Chang, Chia-Lun
    Lin, Hsuan-Yu
    BIODRUGS, 2024, 38 (02) : 287 - 299
  • [29] Safety, Tolerability, and Preliminary Efficacy of Serplulimab, a Novel Anti-PD-1 Antibody, in Patients with Metastatic or Recurrent Solid Tumors: A Phase I Study
    Ching-Liang Ho
    Tsu-Yi Chao
    Chia-Lun Chang
    Hsuan-Yu Lin
    BioDrugs, 2024, 38 : 287 - 299
  • [30] RESULTS OF A PHASE 1, DOSE ESCALATION STUDY TO ASSESS THE SAFETY, EFFICACY AND PHARMACOKINETICS OF SILTUXIMAB, AN ANTI-IL-6 ANTIBODY IN PATIENTS WITH SOLID TUMORS
    Kurzrock, R.
    Cohen, S.
    Tabernero, J.
    van Laethem, J.
    Vermeulen, J.
    Tromp, B.
    Bandekar, R.
    Puchalski, T.
    Cornfeld, M.
    Angevin, E.
    ANNALS OF ONCOLOGY, 2010, 21 : 171 - 171
12345